Proteon logo     Print Page | Close Window

SEC Filings

S-1
PROTEON THERAPEUTICS INC filed this Form S-1 on 09/16/2014
Entire Document
 

Table of Contents

        The foregoing tables and calculations are based upon 138,752,300 shares of common stock outstanding as of June 30, 2014, including 134,918,694 shares of common stock after giving effect to the conversion of our outstanding series A, A-1, B, C and D convertible preferred stock, and excludes:

    17,982,120 shares of our common stock issuable upon the exercise of stock options outstanding as of June 30, 2014 at a weighted-average exercise price of $0.22 per share;
    10,471,282 shares of our common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $0.29 per share;
    18,361 shares of common stock reserved for issuance pursuant to future equity awards under our 2006 Equity Incentive Plan; and
    shares of common stock reserved for future issuance under our 2014 Equity Incentive Plan, which will become effective immediately prior to the closing of this offering (including                         shares of common stock reserved for issuances under our 2006 Equity Incentive Plan, which will be added to the shares reserved under the 2014 Equity Incentive Plan upon its effectiveness).

        Furthermore, we may choose to raise additional capital through the sale of equity or convertible debt securities due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. New investors will experience further dilution if any of our outstanding options or warrants are exercised, new options are issued and exercised under our equity incentive plans or we issue additional shares of common stock, other equity securities or convertible debt securities for lower consideration per share than in this offering in the future.

63